-
Publication Venue For
-
Development of a Fluorescence-Based, High-Throughput SARS-CoV-2 3CLpro Reporter Assay..
94.
2020
-
Antigenicity and Immunogenicity of HIV-1 Envelope Trimers Complexed to a Small-Molecule Viral Entry Inhibitor..
94.
2020
-
The Golgi Calcium ATPase Pump Plays an Essential Role in Adeno-associated Virus Trafficking and Transduction..
94.
2020
-
Coevolution of Adeno-associated Virus Capsid Antigenicity and Tropism through a Structure-Guided Approach..
94.
2020
-
Correction for Garrido et al., "Interleukin-15-Stimulated Natural Killer Cells Clear HIV-1-Infected Cells following Latency Reversal Ex Vivo"..
94.
2020
-
Human Cytomegalovirus Glycoprotein B Nucleoside-Modified mRNA Vaccine Elicits Antibody Responses with Greater Durability and Breadth than MF59-Adjuvanted gB Protein Immunization..
94.
2020
-
Expression of CD40L by the ALVAC-Simian Immunodeficiency Virus Vector Abrogates T Cell Responses in Macaques..
94.
2020
-
Impact of Th1 CD4 Follicular Helper T Cell Skewing on Antibody Responses to an HIV-1 Vaccine in Rhesus Macaques..
94.
2020
-
Neutralizing Antibody Induction by HIV-1 Envelope Glycoprotein SOSIP Trimers on Iron Oxide Nanoparticles May Be Impaired by Mannose Binding Lectin..
94.
2020
-
A MUC16 IgG Binding Activity Selects for a Restricted Subset of IgG Enriched for Certain Simian Immunodeficiency Virus Epitope Specificities..
94.
2020
-
Boosting with AIDSVAX B/E Enhances Env Constant Region 1 and 2 Antibody-Dependent Cellular Cytotoxicity Breadth and Potency..
94.
2020
-
Hepatitis C Virus Infection Is Inhibited by a Noncanonical Antiviral Signaling Pathway Targeted by NS3-NS4A..
93.
2019
-
A CRISPR Screen Identifies the Cell Polarity Determinant Crumbs 3 as an Adeno-associated Virus Restriction Factor in Hepatocytes..
93.
2019
-
Correction for Kibler et al., "Replication-Competent NYVAC-KC Yields Improved Immunogenicity to HIV-1 Antigens in Rhesus Macaques Compared to Nonreplicating NYVAC"..
93.
2019
-
Fc Gamma Receptor Polymorphisms Modulated the Vaccine Effect on HIV-1 Risk in the HVTN 505 HIV Vaccine Trial..
93.
2019
-
Human Immunodeficiency Virus C.1086 Envelope gp140 Protein Boosts following DNA/Modified Vaccinia Virus Ankara Vaccination Fail To Enhance Heterologous Anti-V1V2 Antibody Response and Protection against Clade C Simian-Human Immunodeficiency Virus Challenge..
93.
2019
-
Vaccine-Mediated Inhibition of the Transporter Associated with Antigen Processing Is Insufficient To Induce Major Histocompatibility Complex E-Restricted CD8+ T Cells in Nonhuman Primates..
93.
2019
-
Simian-Human Immunodeficiency Virus SHIV.CH505-Infected Infant and Adult Rhesus Macaques Exhibit Similar Env-Specific Antibody Kinetics, despite Distinct T-Follicular Helper and Germinal Center B Cell Landscapes..
93.
2019
-
The Effect of Age on the Immunogenicity of the Live Attenuated Zoster Vaccine Is Predicted by Baseline Regulatory T Cells and Varicella-Zoster Virus-Specific T Cell Immunity..
93.
2019
-
Optimized Mucosal Modified Vaccinia Virus Ankara Prime/Soluble gp120 Boost HIV Vaccination Regimen Induces Antibody Responses Similar to Those of an Intramuscular Regimen..
93.
2019
-
Modulation of Sialic Acid Dependence Influences the Central Nervous System Transduction Profile of Adeno-associated Viruses..
93.
2019
-
Bridging Vaccine-Induced HIV-1 Neutralizing and Effector Antibody Responses in Rabbit and Rhesus Macaque Animal Models..
93.
2019
-
Adaptation of an R5 Simian-Human Immunodeficiency Virus Encoding an HIV Clade A Envelope with or without Ablation of Adaptive Host Immunity: Differential Selection of Viral Mutants..
93.
2019
-
Rare Detection of Antiviral Functions of Polyclonal IgA Isolated from Plasma and Breast Milk Compartments in Women Chronically Infected with HIV-1..
93.
2019
-
Coadministration of CH31 Broadly Neutralizing Antibody Does Not Affect Development of Vaccine-Induced Anti-HIV-1 Envelope Antibody Responses in Infant Rhesus Macaques..
93.
2019
-
Intrahost Dynamics of Human Cytomegalovirus Variants Acquired by Seronegative Glycoprotein B Vaccinees..
93.
2019
-
Replication-Competent NYVAC-KC Yields Improved Immunogenicity to HIV-1 Antigens in Rhesus Macaques Compared to Nonreplicating NYVAC..
93.
2019
-
Adjuvant-Dependent Enhancement of HIV Env-Specific Antibody Responses in Infant Rhesus Macaques..
92.
2018
-
Antisense-Derived HIV-1 Cryptic Epitopes Are Not Major Drivers of Viral Evolution during the Acute Phase of Infection..
92.
2018
-
Engineered Oncolytic Poliovirus PVSRIPO Subverts MDA5-Dependent Innate Immune Responses in Cancer Cells..
92.
2018
-
The Influenza B Virus Hemagglutinin Head Domain Is Less Tolerant to Transposon Mutagenesis than That of the Influenza A Virus..
92.
2018
-
Control of Heterologous Simian Immunodeficiency Virus SIVsmE660 Infection by DNA and Protein Coimmunization Regimens Combined with Different Toll-Like-Receptor-4-Based Adjuvants in Macaques..
92.
2018
-
Reply to Gantt et al., "Higher Expectations for a Vaccine To Prevent Congenital Cytomegalovirus Infection"..
92.
2018
-
Novel Strategy To Adapt Simian-Human Immunodeficiency Virus E1 Carrying env from an RV144 Volunteer to Rhesus Macaques: Coreceptor Switch and Final Recovery of a Pathogenic Virus with Exclusive R5 Tropism..
92.
2018
-
Interleukin-15-Stimulated Natural Killer Cells Clear HIV-1-Infected Cells following Latency Reversal Ex Vivo..
92.
2018
-
Importance of Neutralizing Monoclonal Antibodies Targeting Multiple Antigenic Sites on the Middle East Respiratory Syndrome Coronavirus Spike Glycoprotein To Avoid Neutralization Escape..
92.
2018
-
Intranasal Live Influenza Vaccine Priming Elicits Localized B Cell Responses in Mediastinal Lymph Nodes..
92.
2018
-
HIV-1 Envelope Glycoproteins from Diverse Clades Differentiate Antibody Responses and Durability among Vaccinees..
92.
2018
-
Immunogenicity in Rabbits of HIV-1 SOSIP Trimers from Clades A, B, and C, Given Individually, Sequentially, or in Combination..
92.
2018
-
Immunogenicity of NYVAC Prime-Protein Boost Human Immunodeficiency Virus Type 1 Envelope Vaccination and Simian-Human Immunodeficiency Virus Challenge of Nonhuman Primates..
92.
2018
-
A Trimeric HIV-1 Envelope gp120 Immunogen Induces Potent and Broad Anti-V1V2 Loop Antibodies against HIV-1 in Rabbits and Rhesus Macaques..
92.
2018
-
Neutralizing Activity of Broadly Neutralizing Anti-HIV-1 Antibodies against Clade B Clinical Isolates Produced in Peripheral Blood Mononuclear Cells..
92.
2018
-
c-Myc Represses Transcription of Epstein-Barr Virus Latent Membrane Protein 1 Early after Primary B Cell Infection..
92.
2018
-
Correction for Hraber et al., "Panels of HIV-1 Subtype C Env Reference Strains for Standardized Neutralization Assessments"..
92.
2018
-
HIV-1 gp120 and Modified Vaccinia Virus Ankara (MVA) gp140 Boost Immunogens Increase Immunogenicity of a DNA/MVA HIV-1 Vaccine..
91.
2017
-
Pathogenic Correlates of Simian Immunodeficiency Virus-Associated B Cell Dysfunction..
91.
2017
-
HIV DNA-Adenovirus Multiclade Envelope Vaccine Induces gp41 Antibody Immunodominance in Rhesus Macaques..
91.
2017
-
Increased, Durable B-Cell and ADCC Responses Associated with T-Helper Cell Responses to HIV-1 Envelope in Macaques Vaccinated with gp140 Occluded at the CD4 Receptor Binding Site..
91.
2017
-
Panels of HIV-1 Subtype C Env Reference Strains for Standardized Neutralization Assessments..
91.
2017
-
Reducing V3 Antigenicity and Immunogenicity on Soluble, Native-Like HIV-1 Env SOSIP Trimers..
91.
2017
-
Glycosylation Benchmark Profile for HIV-1 Envelope Glycoprotein Production Based on Eleven Env Trimers..
91.
2017
-
HIV/AIDS Vaccine Candidates Based on Replication-Competent Recombinant Poxvirus NYVAC-C-KC Expressing Trimeric gp140 and Gag-Derived Virus-Like Particles or Lacking the Viral Molecule B19 That Inhibits Type I Interferon Activate Relevant HIV-1-Specific B and T Cell Immune Functions in Nonhuman Primates..
91.
2017
-
Maternal Binding and Neutralizing IgG Responses Targeting the C-Terminal Region of the V3 Loop Are Predictive of Reduced Peripartum HIV-1 Transmission Risk..
91.
2017
-
Superiority in Rhesus Macaques of Targeting HIV-1 Env gp140 to CD40 versus LOX-1 in Combination with Replication-Competent NYVAC-KC for Induction of Env-Specific Antibody and T Cell Responses..
91.
2017
-
Viral Epitranscriptomics..
91.
2017
-
Influence of the Envelope gp120 Phe 43 Cavity on HIV-1 Sensitivity to Antibody-Dependent Cell-Mediated Cytotoxicity Responses..
91.
2017
-
RPLP1 and RPLP2 Are Essential Flavivirus Host Factors That Promote Early Viral Protein Accumulation..
91.
2017
-
Broadly Neutralizing Antibodies Display Potential for Prevention of HIV-1 Infection of Mucosal Tissue Superior to That of Nonneutralizing Antibodies..
91.
2017
-
Deep Sequencing of Influenza A Virus from a Human Challenge Study Reveals a Selective Bottleneck and Only Limited Intrahost Genetic Diversification..
90:11247-11258.
2016
-
Fc Receptor-Mediated Activities of Env-Specific Human Monoclonal Antibodies Generated from Volunteers Receiving the DNA Prime-Protein Boost HIV Vaccine DP6-001..
90:10362-10378.
2016
-
Increased Protein Degradation Improves Influenza Virus Nucleoprotein-Specific CD8+ T Cell Activation In Vitro but Not in C57BL/6 Mice..
90:10209-10219.
2016
-
Characterization of Simian Immunodeficiency Virus Variants Anatomically Compartmentalized in Plasma and Milk in Chronically Infected African Green Monkeys..
90:8795-8808.
2016
-
Induction of Heterologous Tier 2 HIV-1-Neutralizing and Cross-Reactive V1/V2-Specific Antibodies in Rabbits by Prime-Boost Immunization..
90:8644-8660.
2016
-
Virus-Like Particles Displaying Trimeric Simian Immunodeficiency Virus (SIV) Envelope gp160 Enhance the Breadth of DNA/Modified Vaccinia Virus Ankara SIV Vaccine-Induced Antibody Responses in Rhesus Macaques..
90:8842-8854.
2016
-
Optimization of the Solubility of HIV-1-Neutralizing Antibody 10E8 through Somatic Variation and Structure-Based Design..
90:5899-5914.
2016
-
Superior Efficacy of a Human Immunodeficiency Virus Vaccine Combined with Antiretroviral Prevention in Simian-Human Immunodeficiency Virus-Challenged Nonhuman Primates..
90:5315-5328.
2016
-
Antibodies Elicited by Multiple Envelope Glycoprotein Immunogens in Primates Neutralize Primary Human Immunodeficiency Viruses (HIV-1) Sensitized by CD4-Mimetic Compounds..
90:5031-5046.
2016
-
Combined HIV-1 Envelope Systemic and Mucosal Immunization of Lactating Rhesus Monkeys Induces a Robust Immunoglobulin A Isotype B Cell Response in Breast Milk..
90:4951-4965.
2016
-
Derivation and Characterization of a CD4-Independent, Non-CD4-Tropic Simian Immunodeficiency Virus..
90:4966-4980.
2016
-
Potential To Streamline Heterologous DNA Prime and NYVAC/Protein Boost HIV Vaccine Regimens in Rhesus Macaques by Employing Improved Antigens..
90:4133-4149.
2016
-
A Highly Conserved Residue of the HIV-1 gp120 Inner Domain Is Important for Antibody-Dependent Cellular Cytotoxicity Responses Mediated by Anti-cluster A Antibodies..
90:2127-2134.
2016
-
Enhanced Immune Responses to HIV-1 Envelope Elicited by a Vaccine Regimen Consisting of Priming with Newcastle Disease Virus Expressing HIV gp160 and Boosting with gp120 and SOSIP gp140 Proteins..
90:1682-1686.
2016
-
New Member of the V1V2-Directed CAP256-VRC26 Lineage That Shows Increased Breadth and Exceptional Potency..
90:76-91.
2016
-
Replication-Competent Influenza B Reporter Viruses as Tools for Screening Antivirals and Antibodies..
89:12226-12231.
2015
-
Breast Milk of HIV-Positive Mothers Has Potent and Species-Specific In Vivo HIV-Inhibitory Activity..
89:10868-10878.
2015
-
Cooperation between the Hepatitis C Virus p7 and NS5B Proteins Enhances Virion Infectivity..
89:11523-11533.
2015
-
Epstein-Barr Viruses (EBVs) Deficient in EBV-Encoded RNAs Have Higher Levels of Latent Membrane Protein 2 RNA Expression in Lymphoblastoid Cell Lines and Efficiently Establish Persistent Infections in Humanized Mice..
89:11711-11714.
2015
-
Phenotypic Correlates of HIV-1 Macrophage Tropism..
89:11294-11311.
2015
-
Association of HIV-1 Envelope-Specific Breast Milk IgA Responses with Reduced Risk of Postnatal Mother-to-Child Transmission of HIV-1..
89:9952-9961.
2015
-
Elite Control, Gut CD4 T Cell Sparing, and Enhanced Mucosal T Cell Responses in Macaca nemestrina Infected by a Simian Immunodeficiency Virus Lacking a gp41 Trafficking Motif..
89:10156-10175.
2015
-
Soluble Envelope Glycoprotein Trimers from a CD4-Independent HIV-1 Elicit Antibody-Dependent Cellular Cytotoxicity-Mediating Antibodies in Guinea Pigs..
89:10707-10711.
2015
-
A Screen for Extracellular Signal-Regulated Kinase-Primed Glycogen Synthase Kinase 3 Substrates Identifies the p53 Inhibitor iASPP..
89:9232-9241.
2015
-
An Enhanced Synthetic Multiclade DNA Prime Induces Improved Cross-Clade-Reactive Functional Antibodies when Combined with an Adjuvanted Protein Boost in Nonhuman Primates..
89:9154-9166.
2015
-
Cocrystal Structures of Antibody N60-i3 and Antibody JR4 in Complex with gp120 Define More Cluster A Epitopes Involved in Effective Antibody-Dependent Effector Function against HIV-1..
89:8840-8854.
2015
-
Epidemiology, Evolution, and Recent Outbreaks of Avian Influenza Virus in China..
89:8671-8676.
2015
-
Rapid Development of gp120-Focused Neutralizing B Cell Responses during Acute Simian Immunodeficiency Virus Infection of African Green Monkeys..
89:9485-9498.
2015
-
Comparable Antigenicity and Immunogenicity of Oligomeric Forms of a Novel, Acute HIV-1 Subtype C gp145 Envelope for Use in Preclinical and Clinical Vaccine Research..
89:7478-7493.
2015
-
Comparative Analysis of the Glycosylation Profiles of Membrane-Anchored HIV-1 Envelope Glycoprotein Trimers and Soluble gp140..
89:8245-8257.
2015
-
Head-to-Head Comparison of Poxvirus NYVAC and ALVAC Vectors Expressing Identical HIV-1 Clade C Immunogens in Prime-Boost Combination with Env Protein in Nonhuman Primates..
89:8525-8539.
2015
-
Inhibitory Effect of Individual or Combinations of Broadly Neutralizing Antibodies and Antiviral Reagents against Cell-Free and Cell-to-Cell HIV-1 Transmission..
89:7813-7828.
2015
-
Two-Year Follow-Up of Macaques Developing Intermittent Control of the Human Immunodeficiency Virus Homolog Simian Immunodeficiency Virus SIVmac251 in the Chronic Phase of Infection..
89:7521-7535.
2015
-
Vaccine-Induced Linear Epitope-Specific Antibodies to Simian Immunodeficiency Virus SIVmac239 Envelope Are Distinct from Those Induced to the Human Immunodeficiency Virus Type 1 Envelope in Nonhuman Primates..
89:8643-8650.
2015
-
MAVS Coordination of Antiviral Innate Immunity..
89:6974-6977.
2015
-
Comparison of Immunogenicity in Rhesus Macaques of Transmitted-Founder, HIV-1 Group M Consensus, and Trivalent Mosaic Envelope Vaccines Formulated as a DNA Prime, NYVAC, and Envelope Protein Boost..
89:6462-6480.
2015
-
Sustained Delivery of a Broadly Neutralizing Antibody in Nonhuman Primates Confers Long-Term Protection against Simian/Human Immunodeficiency Virus Infection..
89:5895-5903.
2015
-
CD40L-adjuvanted DNA/modified vaccinia virus Ankara simian immunodeficiency virus (SIV) vaccine enhances protection against neutralization-resistant mucosal SIV infection..
89:4690-4695.
2015
-
DNA vaccine molecular adjuvants SP-D-BAFF and SP-D-APRIL enhance anti-gp120 immune response and increase HIV-1 neutralizing antibody titers..
89:4158-4169.
2015
-
Unique glycan signatures regulate adeno-associated virus tropism in the developing brain..
89:3976-3987.
2015
-
Improving neutralization potency and breadth by combining broadly reactive HIV-1 antibodies targeting major neutralization epitopes..
89:2659-2671.
2015
-
Polyreactivity and autoreactivity among HIV-1 antibodies..
89:784-798.
2015
-
Enhanced potency of a broadly neutralizing HIV-1 antibody in vitro improves protection against lentiviral infection in vivo..
88:12669-12682.
2014
-
Impact of clade, geography, and age of the epidemic on HIV-1 neutralization by antibodies..
88:12623-12643.
2014
-
Induction of viral, 7-methyl-guanosine cap-independent translation and oncolysis by mitogen-activated protein kinase-interacting kinase-mediated effects on the serine/arginine-rich protein kinase..
88:13135-13148.
2014
-
Mitogen-activated protein kinase-interacting kinase regulates mTOR/AKT signaling and controls the serine/arginine-rich protein kinase-responsive type 1 internal ribosome entry site-mediated translation and viral oncolysis..
88:13149-13160.
2014
-
Structural definition of an antibody-dependent cellular cytotoxicity response implicated in reduced risk for HIV-1 infection..
88:12895-12906.
2014
-
Viruses and RNA interference: issues and controversies..
88:12934-12936.
2014
-
Inactivation of the human papillomavirus E6 or E7 gene in cervical carcinoma cells by using a bacterial CRISPR/Cas RNA-guided endonuclease..
88:11965-11972.
2014
-
CD40L-adjuvanted DNA/modified vaccinia virus Ankara simian immunodeficiency virus SIV239 vaccine enhances SIV-specific humoral and cellular immunity and improves protection against a heterologous SIVE660 mucosal challenge..
88:9579-9589.
2014
-
Envelope glycoprotein binding to the integrin α4β7 is not a general property of most HIV-1 strains..
88:10767-10777.
2014
-
Transcriptional and posttranscriptional regulation of cytokine gene expression in HIV-1 antigen-specific CD8+ T cells that mediate virus inhibition..
88:9514-9528.
2014
-
Analysis of HLA A*02 association with vaccine efficacy in the RV144 HIV-1 vaccine trial..
88:8242-8255.
2014
-
Vaccine-induced HIV-1 envelope gp120 constant region 1-specific antibodies expose a CD4-inducible epitope and block the interaction of HIV-1 gp140 with galactosylceramide..
88:9406-9417.
2014
-
HIV-1 vaccine-induced C1 and V2 Env-specific antibodies synergize for increased antiviral activities..
88:7715-7726.
2014
-
Replication of many human viruses is refractory to inhibition by endogenous cellular microRNAs..
88:8065-8076.
2014
-
CD4-mimetic small molecules sensitize human immunodeficiency virus to vaccine-elicited antibodies..
88:6542-6555.
2014
-
Capacity for infectious HIV-1 virion capture differs by envelope antibody specificity..
88:5165-5170.
2014
-
Identification of novel, highly expressed retroviral microRNAs in cells infected by bovine foamy virus..
88:4679-4686.
2014
-
Global panel of HIV-1 Env reference strains for standardized assessments of vaccine-elicited neutralizing antibodies..
88:2489-2507.
2014
-
Interaction with cellular CD4 exposes HIV-1 envelope epitopes targeted by antibody-dependent cell-mediated cytotoxicity..
88:2633-2644.
2014
-
Toll-like receptor 7/8 (TLR7/8) and TLR9 agonists cooperate to enhance HIV-1 envelope antibody responses in rhesus macaques..
88:3329-3339.
2014
-
A vaccine against CCR5 protects a subset of macaques upon intravaginal challenge with simian immunodeficiency virus SIVmac251..
88:2011-2024.
2014
-
Evolutionary conservation of primate lymphocryptovirus microRNA targets..
88:1617-1635.
2014
-
Evolution and diversity in human herpes simplex virus genomes..
88:1209-1227.
2014
-
Resistance to infection, early and persistent suppression of simian immunodeficiency virus SIVmac251 viremia, and significant reduction of tissue viral burden after mucosal vaccination in female rhesus macaques..
88:212-224.
2014
-
Robust neutralizing antibodies elicited by HIV-1 JRFL envelope glycoprotein trimers in nonhuman primates..
87:13239-13251.
2013
-
Effects of cellular activation on anti-HIV-1 restriction factor expression profile in primary cells..
87:11924-11929.
2013
-
Epstein-Barr virus induces global changes in cellular mRNA isoform usage that are important for the maintenance of latency..
87:12291-12301.
2013
-
Neutralizing IgG at the portal of infection mediates protection against vaginal simian/human immunodeficiency virus challenge..
87:11604-11616.
2013
-
Hemagglutinin stalk-based universal vaccine constructs protect against group 2 influenza A viruses..
87:10435-10446.
2013
-
Lack of B cell dysfunction is associated with functional, gp120-dominant antibody responses in breast milk of simian immunodeficiency virus-infected African green monkeys..
87:11121-11134.
2013
-
Transient compartmentalization of simian immunodeficiency virus variants in the breast milk of african green monkeys..
87:11292-11299.
2013
-
A novel rabbit monoclonal antibody platform to dissect the diverse repertoire of antibody epitopes for HIV-1 Env immunogen design..
87:10232-10243.
2013
-
Evolutionarily conserved epitopes on human immunodeficiency virus type 1 (HIV-1) and feline immunodeficiency virus reverse transcriptases detected by HIV-1-infected subjects..
87:10004-10015.
2013
-
Heavy chain-only IgG2b llama antibody effects near-pan HIV-1 neutralization by recognizing a CD4-induced epitope that includes elements of coreceptor- and CD4-binding sites..
87:10173-10181.
2013
-
Immune focusing and enhanced neutralization induced by HIV-1 gp140 chemical cross-linking..
87:10163-10172.
2013
-
Residue-level prediction of HIV-1 antibody epitopes based on neutralization of diverse viral strains..
87:10047-10058.
2013
-
Quantitative and qualitative differences in the T cell response to HIV in uninfected Ugandans exposed or unexposed to HIV-infected partners..
87:9053-9063.
2013
-
Comparison of viral Env proteins from acute and chronic infections with subtype C human immunodeficiency virus type 1 identifies differences in glycosylation and CCR5 utilization and suggests a new strategy for immunogen design..
87:7218-7233.
2013
-
Infectious virion capture by HIV-1 gp120-specific IgG from RV144 vaccinees..
87:7828-7836.
2013
-
Mucosal immunization of lactating female rhesus monkeys with a transmitted/founder HIV-1 envelope induces strong Env-specific IgA antibody responses in breast milk..
87:6986-6999.
2013
-
Mutational inactivation of herpes simplex virus 1 microRNAs identifies viral mRNA targets and reveals phenotypic effects in culture..
87:6589-6603.
2013
-
A cluster of virus-encoded microRNAs accelerates acute systemic Epstein-Barr virus infection but does not significantly enhance virus-induced oncogenesis in vivo..
87:5437-5446.
2013
-
Antibody-DEPENDENT, FcγRI-mediated neutralization of HIV-1 in TZM-bl cells occurs independently of phagocytosis..
87:5287-5290.
2013
-
Dendritic cell immunoreceptor regulates Chikungunya virus pathogenesis in mice..
87:5697-5706.
2013
-
Identification of an HIV-1 clade A envelope that exhibits broad antigenicity and neutralization sensitivity and elicits antibodies targeting three distinct epitopes..
87:5372-5383.
2013
-
Antigenicity and immunogenicity of transmitted/founder, consensus, and chronic envelope glycoproteins of human immunodeficiency virus type 1..
87:4185-4201.
2013
-
Immunogenicity of a vaccine regimen composed of simian immunodeficiency virus DNA, rMVA, and viral particles administered to female rhesus macaques via four different mucosal routes..
87:4738-4750.
2013
-
Biophysical and ultrastructural characterization of adeno-associated virus capsid uncoating and genome release..
87:2994-3002.
2013
-
Protection afforded by an HIV vaccine candidate in macaques depends on the dose of SIVmac251 at challenge exposure..
87:3538-3548.
2013
-
Antibodies with high avidity to the gp120 envelope protein in protection from simian immunodeficiency virus SIV(mac251) acquisition in an immunization regimen that mimics the RV-144 Thai trial..
87:1708-1719.
2013
-
Antigenicity and immunogenicity of RV144 vaccine AIDSVAX clade E envelope immunogen is enhanced by a gp120 N-terminal deletion..
87:1554-1568.
2013
-
Antibody-dependent cellular cytotoxicity-mediating antibodies from an HIV-1 vaccine efficacy trial target multiple epitopes and preferentially use the VH1 gene family..
86:11521-11532.
2012
-
Analysis of Epstein-Barr virus-regulated host gene expression changes through primary B-cell outgrowth reveals delayed kinetics of latent membrane protein 1-mediated NF-κB activation..
86:11096-11106.
2012
-
Glycan binding avidity determines the systemic fate of adeno-associated virus type 9..
86:10408-10417.
2012
-
Memory CD4(+) T lymphocytes in the gastrointestinal tract are a major source of cell-associated simian immunodeficiency virus in chronic nonpathogenic infection of African green monkeys..
86:11380-11385.
2012
-
A short segment of the HIV-1 gp120 V1/V2 region is a major determinant of resistance to V1/V2 neutralizing antibodies..
86:8319-8323.
2012
-
Pathogenicity and mucosal transmissibility of the R5-tropic simian/human immunodeficiency virus SHIV(AD8) in rhesus macaques: implications for use in vaccine studies..
86:8516-8526.
2012
-
Single amino acid modification of adeno-associated virus capsid changes transduction and humoral immune profiles..
86:7752-7759.
2012
-
HIV-1 gp120 vaccine induces affinity maturation in both new and persistent antibody clonal lineages..
86:7496-7507.
2012
-
The development of CD4 binding site antibodies during HIV-1 infection..
86:7588-7595.
2012
-
A novel variant marking HLA-DP expression levels predicts recovery from hepatitis B virus infection..
86:6979-6985.
2012
-
Human galectin 3 binding protein interacts with recombinant adeno-associated virus type 6..
86:6620-6631.
2012
-
Initial HIV-1 antigen-specific CD8+ T cells in acute HIV-1 infection inhibit transmitted/founder virus replication..
86:6835-6846.
2012
-
The Epstein-Barr virus (EBV)-induced tumor suppressor microRNA MiR-34a is growth promoting in EBV-infected B cells..
86:6889-6898.
2012
-
Passively transmitted gp41 antibodies in babies born from HIV-1 subtype C-seropositive women: correlation between fine specificity and protection..
86:4129-4138.
2012
-
Replicating adenovirus-simian immunodeficiency virus (SIV) recombinant priming and envelope protein boosting elicits localized, mucosal IgA immunity in rhesus macaques correlated with delayed acquisition following a repeated low-dose rectal SIV(mac251) challenge..
86:4644-4657.
2012
-
Two distinct broadly neutralizing antibody specificities of different clonal lineages in a single HIV-1-infected donor: implications for vaccine design..
86:4688-4692.
2012
-
Attenuation of neurovirulence, biodistribution, and shedding of a poliovirus:rhinovirus chimera after intrathalamic inoculation in Macaca fascicularis..
86:2750-2759.
2012
-
Control of innate immune signaling and membrane targeting by the Hepatitis C virus NS3/4A protease are governed by the NS3 helix α0..
86:3112-3120.
2012
-
Generation of transmitted/founder HIV-1 infectious molecular clones and characterization of their replication capacity in CD4 T lymphocytes and monocyte-derived macrophages..
86:2715-2728.
2012
-
Targeting HIV-1 envelope glycoprotein trimers to B cells by using APRIL improves antibody responses..
86:2488-2500.
2012
-
High-mannose glycan-dependent epitopes are frequently targeted in broad neutralizing antibody responses during human immunodeficiency virus type 1 infection..
86:2153-2164.
2012
-
Engineering, expression, purification, and characterization of stable clade A/B recombinant soluble heterotrimeric gp140 proteins..
86:128-142.
2012
-
Targeted entry via somatostatin receptors using a novel modified retrovirus glycoprotein that delivers genes at levels comparable to those of wild-type viral glycoproteins..
86:373-381.
2012
-
Three-dimensional structures of soluble CD4-bound states of trimeric simian immunodeficiency virus envelope glycoproteins determined by using cryo-electron tomography..
85:12114-12123.
2011
-
Cross-reactive HIV-1-neutralizing human monoclonal antibodies identified from a patient with 2F5-like antibodies..
85:11401-11408.
2011
-
Differential reactivity of germ line allelic variants of a broadly neutralizing HIV-1 antibody to a gp41 fusion intermediate conformation..
85:11725-11731.
2011
-
Dynamic antibody specificities and virion concentrations in circulating immune complexes in acute to chronic HIV-1 infection..
85:11196-11207.
2011
-
Polyclonal B cell responses to conserved neutralization epitopes in a subset of HIV-1-infected individuals..
85:11502-11519.
2011
-
Analysis of a clonal lineage of HIV-1 envelope V2/V3 conformational epitope-specific broadly neutralizing antibodies and their inferred unmutated common ancestors..
85:9998-10009.
2011
-
Fitness costs and diversity of the cytotoxic T lymphocyte (CTL) response determine the rate of CTL escape during acute and chronic phases of HIV infection..
85:10518-10528.
2011
-
Primary infection by a human immunodeficiency virus with atypical coreceptor tropism..
85:10669-10681.
2011
-
The members of an Epstein-Barr virus microRNA cluster cooperate to transform B lymphocytes..
85:9801-9810.
2011
-
HIV-specific functional antibody responses in breast milk mirror those in plasma and are primarily mediated by IgG antibodies..
85:9555-9567.
2011
-
High cell-free virus load and robust autologous humoral immune responses in breast milk of simian immunodeficiency virus-infected african green monkeys..
85:9517-9526.
2011
-
Mechanism of neutralization by the broadly neutralizing HIV-1 monoclonal antibody VRC01..
85:8954-8967.
2011
-
Phenotypic and immunologic comparison of clade B transmitted/founder and chronic HIV-1 envelope glycoproteins..
85:8514-8527.
2011
-
epitopes immediately below the base of the V3 loop of gp120 as targets for the initial autologous neutralizing antibody response in two HIV-1 subtype B-infected individuals..
85:9286-9299.
2011
-
Characterization of glycosylation profiles of HIV-1 transmitted/founder envelopes by mass spectrometry..
85:8270-8284.
2011
-
Isolation of a monoclonal antibody that targets the alpha-2 helix of gp120 and represents the initial autologous neutralizing-antibody response in an HIV-1 subtype C-infected individual..
85:7719-7729.
2011
-
The genetic bottleneck in vertical transmission of subtype C HIV-1 is not driven by selection of especially neutralization-resistant virus from the maternal viral population..
85:8253-8262.
2011
-
An HIV-1 gp120 envelope human monoclonal antibody that recognizes a C1 conformational epitope mediates potent antibody-dependent cellular cytotoxicity (ADCC) activity and defines a common ADCC epitope in human HIV-1 serum..
85:7029-7036.
2011
-
Antibody-dependent cell-mediated cytotoxicity in simian immunodeficiency virus-infected rhesus monkeys..
85:6906-6912.
2011
-
Evolution of drug-resistant viral populations during interruption of antiretroviral therapy..
85:6403-6415.
2011
-
Immunization with recombinant HLA classes I and II, HIV-1 gp140, and SIV p27 elicits protection against heterologous SHIV infection in rhesus macaques..
85:6442-6452.
2011
-
Adaptation of an ICAM-1-tropic enterovirus to the mouse respiratory tract..
85:5606-5617.
2011
-
Significant protection against high-dose simian immunodeficiency virus challenge conferred by a new prime-boost vaccine regimen..
85:5764-5772.
2011
-
Differences in HIV-specific T cell responses between HIV-exposed and -unexposed HIV-seronegative individuals..
85:3507-3516.
2011
-
Origin and evolution of HIV-1 in breast milk determined by single-genome amplification and sequencing..
85:2751-2763.
2011
-
Nonneutralizing HIV-1 gp41 envelope cluster II human monoclonal antibodies show polyreactivity for binding to phospholipids and protein autoantigens..
85:1340-1347.
2011
-
Virally induced cellular microRNA miR-155 plays a key role in B-cell immortalization by Epstein-Barr virus..
84:11670-11678.
2010
-
Low-dose mucosal simian immunodeficiency virus infection restricts early replication kinetics and transmitted virus variants in rhesus monkeys..
84:10406-10412.
2010
-
Viral cell death inhibitor MC159 enhances innate immunity against vaccinia virus infection..
84:10467-10476.
2010
-
Limited contribution of mucosal IgA to Simian immunodeficiency virus (SIV)-specific neutralizing antibody response and virus envelope evolution in breast milk of SIV-infected, lactating rhesus monkeys..
84:8209-8218.
2010
-
HIV-1 resistance to CCR5 antagonists associated with highly efficient use of CCR5 and altered tropism on primary CD4+ T cells..
84:6505-6514.
2010
-
Wide variation in the multiplicity of HIV-1 infection among injection drug users..
84:6241-6247.
2010
-
A human herpesvirus microRNA inhibits p21 expression and attenuates p21-mediated cell cycle arrest..
84:5229-5237.
2010
-
Phenotypic and functional profile of HIV-inhibitory CD8 T cells elicited by natural infection and heterologous prime/boost vaccination..
84:4998-5006.
2010
-
Breadth of neutralizing antibodies elicited by stable, homogeneous clade A and clade C HIV-1 gp140 envelope trimers in guinea pigs..
84:3270-3279.
2010
-
Quaternary epitope specificities of anti-HIV-1 neutralizing antibodies generated in rhesus macaques infected by the simian/human immunodeficiency virus SHIVSF162P4..
84:3443-3453.
2010
-
Tiered categorization of a diverse panel of HIV-1 Env pseudoviruses for assessment of neutralizing antibodies..
84:1439-1452.
2010
-
Herpes simplex virus proteins ICP27 and UL47 associate with polyadenylate-binding protein and control its subcellular distribution..
84:270-279.
2010
-
Identification of viral microRNAs expressed in human sacral ganglia latently infected with herpes simplex virus 2..
84:1189-1192.
2010
-
In-depth analysis of Kaposi's sarcoma-associated herpesvirus microRNA expression provides insights into the mammalian microRNA-processing machinery..
84:695-703.
2010
-
FAT10: a novel mediator of Vpr-induced apoptosis in human immunodeficiency virus-associated nephropathy..
83:11983-11988.
2009
-
Analysis of human alphaherpesvirus microRNA expression in latently infected human trigeminal ganglia..
83:10677-10683.
2009
-
Derivation and characterization of a simian immunodeficiency virus SIVmac239 variant with tropism for CXCR4..
83:9911-9922.
2009
-
Effect of B-cell depletion on viral replication and clinical outcome of simian immunodeficiency virus infection in a natural host..
83:10347-10357.
2009
-
Identification of ongoing human immunodeficiency virus type 1 (HIV-1) replication in residual viremia during recombinant HIV-1 poxvirus immunizations in patients with clinically undetectable viral loads on durable suppressive highly active antiretroviral therapy..
83:9731-9742.
2009
-
Stable docking of neutralizing human immunodeficiency virus type 1 gp41 membrane-proximal external region monoclonal antibodies 2F5 and 4E10 is dependent on the membrane immersion depth of their epitope regions..
83:10211-10223.
2009
-
Antibody specificities associated with neutralization breadth in plasma from human immunodeficiency virus type 1 subtype C-infected blood donors..
83:8925-8937.
2009
-
Protective efficacy of a single immunization of a chimeric adenovirus vector-based vaccine against simian immunodeficiency virus challenge in rhesus monkeys..
83:9584-9590.
2009
-
T-cell vaccine strategies for human immunodeficiency virus, the virus with a thousand faces..
83:8300-8314.
2009
-
Evidence that ecotropic murine leukemia virus contamination in TZM-bl cells does not affect the outcome of neutralizing antibody assays with human immunodeficiency virus type 1..
83:8289-8292.
2009
-
Utilization of immunoglobulin G Fc receptors by human immunodeficiency virus type 1: a specific role for antibodies against the membrane-proximal external region of gp41..
83:7397-7410.
2009
-
Cytotoxic-T-lymphocyte-mediated elimination of target cells transduced with engineered adeno-associated virus type 2 vector in vivo..
83:6817-6824.
2009
-
Identification of Ongoing HIV-1 Replication in Residual Viremia during Recombinant HIV-1 Poxvirus Immunizations in Patients with Clinically Undetectable Viral Loads on Durable Suppressive HAART.
2009
-
Recombinant Mycobacterium bovis BCG prime-recombinant adenovirus boost vaccination in rhesus monkeys elicits robust polyfunctional simian immunodeficiency virus-specific T-cell responses..
83:5505-5513.
2009
-
Preclinical studies of human immunodeficiency virus/AIDS vaccines: inverse correlation between avidity of anti-Env antibodies and peak postchallenge viremia..
83:4102-4111.
2009
-
High specific infectivity of plasma virus from the pre-ramp-up and ramp-up stages of acute simian immunodeficiency virus infection..
83:3288-3297.
2009
-
In vivo gp41 antibodies targeting the 2F5 monoclonal antibody epitope mediate human immunodeficiency virus type 1 neutralization breadth..
83:3617-3625.
2009
-
Quantitating the multiplicity of infection with human immunodeficiency virus type 1 subtype C reveals a non-poisson distribution of transmitted variants..
83:3556-3567.
2009
-
Comparisons of CD8+ T cells specific for human immunodeficiency virus, hepatitis C virus, and cytomegalovirus reveal differences in frequency, immunodominance, phenotype, and interleukin-2 responsiveness..
83:2728-2742.
2009
-
Expanded breadth of the T-cell response to mosaic human immunodeficiency virus type 1 envelope DNA vaccination..
83:2201-2215.
2009
-
MDM2-dependent inhibition of p53 is required for Epstein-Barr virus B-cell growth transformation and infected-cell survival..
83:2491-2499.
2009
-
Partial protection of Simian immunodeficiency virus (SIV)-infected rhesus monkeys against superinfection with a heterologous SIV isolate..
83:2686-2696.
2009
-
Neutralization-sensitive R5-tropic simian-human immunodeficiency virus SHIV-2873Nip, which carries env isolated from an infant with a recent HIV clade C infection..
83:1422-1432.
2009
-
Correlation of vaccine-elicited systemic and mucosal nonneutralizing antibody activities with reduced acute viremia following intrarectal simian immunodeficiency virus SIVmac251 challenge of rhesus macaques..
83:791-801.
2009
-
Equine infectious anemia virus resists the antiretroviral activity of equine APOBEC3 proteins through a packaging-independent mechanism..
82:11889-11901.
2008
-
Initial B-cell responses to transmitted human immunodeficiency virus type 1: virion-binding immunoglobulin M (IgM) and IgG antibodies followed by plasma anti-gp41 antibodies with ineffective control of initial viremia..
82:12449-12463.
2008
-
Profiling the specificity of neutralizing antibodies in a large panel of plasmas from patients chronically infected with human immunodeficiency virus type 1 subtypes B and C..
82:11651-11668.
2008
-
Early B-cell activation after West Nile virus infection requires alpha/beta interferon but not antigen receptor signaling..
82:10964-10974.
2008
-
Improved induction of antibodies against key neutralizing epitopes by human immunodeficiency virus type 1 gp120 DNA prime-protein boost vaccination compared to gp120 protein-only vaccination..
82:7369-7378.
2008
-
Induction of plasma (TRAIL), TNFR-2, Fas ligand, and plasma microparticles after human immunodeficiency virus type 1 (HIV-1) transmission: implications for HIV-1 vaccine design..
82:7700-7710.
2008
-
An engineered Saccharomyces cerevisiae strain binds the broadly neutralizing human immunodeficiency virus type 1 antibody 2G12 and elicits mannose-specific gp120-binding antibodies..
82:6447-6457.
2008
-
Antibody is critical for the clearance of murine norovirus infection..
82:6610-6617.
2008
-
Cross-reactive human immunodeficiency virus type 1-neutralizing human monoclonal antibody that recognizes a novel conformational epitope on gp41 and lacks reactivity against self-antigens..
82:6869-6879.
2008
-
Human T-cell leukemia virus type 1 tax attenuates the ATM-mediated cellular DNA damage response..
82:6952-6961.
2008
-
Increased loss of CCR5+ CD45RA- CD4+ T cells in CD8+ lymphocyte-depleted Simian immunodeficiency virus-infected rhesus monkeys..
82:5618-5630.
2008
-
Surface loop dynamics in adeno-associated virus capsid assembly..
82:5178-5189.
2008
-
Induction of Plasma (TRAIL), TNFR-2, Fas Ligand and Plasma Microparticles After HIV-1 Transmission: Implications for HIV-1 Vaccine Design.
2008
-
Deciphering human immunodeficiency virus type 1 transmission and early envelope diversification by single-genome amplification and sequencing..
82:3952-3970.
2008
-
Human immunodeficiency virus type 1 gp41 antibodies that mask membrane proximal region epitopes: antibody binding kinetics, induction, and potential for regulation in acute infection..
82:115-125.
2008
-
Removal of a single N-linked glycan in human immunodeficiency virus type 1 gp120 results in an enhanced ability to induce neutralizing antibody responses..
82:638-651.
2008
-
Increased immunogenicity of a DNA-launched Venezuelan equine encephalitis virus-based replicon DNA vaccine..
81:13412-13423.
2007
-
Inhibition of alpharetrovirus replication by a range of human APOBEC3 proteins..
81:13694-13699.
2007
-
Translation by the adenovirus tripartite leader: elements which determine independence from cap-binding protein complex.
64:2669-2677.
1990
-
Correction for Chakrabarti et al., Robust Neutralizing Antibodies Elicited by HIV-1 JRFL Envelope Glycoprotein Trimers in Nonhuman Primates..
89:887.
2015
-
SMAC Mimetic Plus Triple-Combination Bispecific HIVxCD3 Retargeting Molecules in SHIV.C.CH505-Infected, Antiretroviral Therapy-Suppressed Rhesus Macaques.
2020
-
Priming with a Potent HIV-1 DNA Vaccine Frames the Quality of Immune Responses prior to a Poxvirus and Protein Boost.
2019